NY-KINESSO
23.5.2022 14:06:07 CEST | Business Wire | Press release
Kinesso , IPG’s connected intelligence company, today announced the appointment of four new Regional CEOs. Executives previously in Matterkind leadership roles are being promoted to Kinesso Regional CEOs and will retain their Matterkind leadership responsibilities as well: Matt Ware in APAC, Andy Butters in EMEA, Jorge Chavez in LATAM, and Sean Muzzy in North America. Each will be responsible for ensuring clients have a single, simplified engagement experience with Kinesso and Matterkind, companies that work closely together as part of the data, technology, and media activation backbone for IPG.
The Regional CEO role was created to streamline support for Kinesso’s largest IPG partner, Mediabrands, and to capitalize on growth opportunities as Kinesso continues to evolve its business both inside and outside the IPG network. By appointing leaders who were already in region, Kinesso is building on the strength of Matterkind’s existing international leadership team, all of whom are well positioned to spearhead the design and delivery of integrated solutions across the breadth of Kinesso’s and Matterkind’s offerings.
“Putting Regional CEOs in place supports the kind of horizontal integration that will spark additional innovation at Kinesso,” said Arun Kumar, Chief Data and Technology Officer at IPG and Global CEO at Kinesso. “Innovation happens everywhere. Matt, Andy, Jorge, and Sean will give us a unified, global focus on the challenges we need to solve for our clients – including better connections between their martech and adtech – and will surely be a catalyst for further growth for Kinesso and our clients.”
“I couldn’t be more thrilled for Matt, Andy, Jorge and Sean,” said Erica Schmidt, Global CEO at Matterkind. “They already have a track record of success leading Matterkind’s business in these regions, and I know they will continue to deliver excellence in their new roles.”
The Regional CEOs will serve as a single point of contact for Kinesso and Matterkind services and solutions. Clients will benefit from the end-to-end solution sets and additional innovations Kinesso and Matterkind develop as they work more cross-functionally and globally.
Kinesso’s new Regional CEOs’ bios can be found here .
About Kinesso
Kinesso is a connected intelligence company that builds applications and software solutions, working with agencies and partners to deliver consistent and relevant customer experiences for people across all channels. Kinesso’s technology solutions and services span audience, planning, and activation, delivering insights that drive growth for leading global brands. Kinesso is part of The Interpublic Group of Companies, Inc. (IPG). For more information, visit kinesso.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
